Last updated: May 25, 2026
DIURIL (chlorothiazide) clinical trials update, market analysis, and exclusivity-driven projection
Diuril is the brand name for chlorothiazide, an oral thiazide diuretic. It is off patent for the U.S. market, with multiple generic chlorothiazide products established. Current “clinical trials updates” for Diuril specifically are limited because the active ingredient is long genericized; most recent development activity in the thiazide class targets formulations, combinations, or specific regulatory needs rather than new molecular entities. Market dynamics are therefore driven by generic supply, short formularies, low-cost competitive pricing, and ongoing demand for inexpensive diuretic therapy in hypertension, edema, and related indications rather than by brand-level innovation cycles.
What clinical trials exist for Diuril (chlorothiazide) in 2024–2026?
Short answer: No material, clearly identifiable late-stage (Phase 3) clinical development cycle for Diuril brand chlorothiazide is evident in recent public registries; the practical development footprint is dominated by generic-quality studies, label maintenance, and comparative pharmacology within the thiazide class rather than new efficacy trials for the standalone product.
What does “clinical trials update” mean for an off-patent thiazide like chlorothiazide?
For long-generic small molecules, public trial activity often shows up as:
- Bioequivalence studies (BE) for generic approvals (not new drug development).
- Small, investigator-initiated pharmacodynamic studies (electrolytes, natriuresis, dose-response).
- Formulation or manufacturing process work that supports ANDA lifecycle maintenance rather than novel endpoints.
Which study types you should track for chlorothiazide (Diuril)
- BE studies for oral chlorothiazide tablets or equivalent dosage forms.
- Stability/CMC changes that can trigger bridging studies.
- Subpopulation analyses (elderly, renal impairment) that affect labeling language rather than separate approvals.
What is the current FDA/Orange Book status of Diuril (chlorothiazide)?
Short answer: Diuril’s exclusivity and patent protection for chlorothiazide are not the binding constraints for market access; access is primarily governed by ANDA generic competition and labeling maintenance.
Orange Book listing mechanics for an old thiazide
Because chlorothiazide is a legacy active ingredient, the Orange Book record typically shows:
- Long-standing generic entries for the approved dosage forms.
- Limited relevance of brand-specific unexpired patents for entry timing.
- Patent listings, when present historically, that no longer constrain generic launch because the substance is off patent.
What that implies for launch timing
- There is no realistic “brand restart” exclusivity pathway at the molecule level.
- Market entry is constrained by supply chain, manufacturing capacity, and label/quality consistency more than by legal exclusivity.
When does Diuril chlorothiazide lose exclusivity in the U.S.?
Short answer: Chlorothiazide is fully generic in the U.S.; exclusivity and relevant patent terms are long expired for the active ingredient.
Implication for investors and licensors
- Any new revenue upside depends on differentiation at the product level (packaging, supply reliability, contracting) rather than on patent-driven exclusivity.
What patents protect chlorothiazide (Diuril) today, and what risks matter for generics?
Short answer: Patent risk for generics is mostly historical. For an established molecule, any remaining risks typically stem from formulation-specific patents tied to a particular dosage form or manufacturing method, not from the active ingredient’s core chemistry.
How generic entry risks typically present for legacy diuretics
- Narrow formulation or process patents (if any) tied to a specific product.
- Litigation risk from asserted patents is generally low for fully generic molecules unless a newer reformulation exists.
- Most competitive risk is economic, not IP.
How many clinical outcomes and endpoints define the value proposition for Diuril?
Short answer: For chlorothiazide, clinical relevance centers on diuresis-related endpoints and standard hypertension/edema management metrics rather than novel biomarkers.
Endpoints used in standard chlorothiazide evaluation
- Blood pressure reduction (hypertension).
- Fluid reduction and edema control (diuresis).
- Electrolyte safety signals (potassium, sodium, magnesium).
- Renal function and metabolic effect monitoring.
What “evidence strength” means for market projections
For a generic diuretic:
- Physicians treat it as substitutable within the class.
- Switching is primarily driven by tolerability, cost, and availability.
- Outcome-based differentiation is limited unless a product solves a practical adherence or supply problem.
How does Diuril compare with other thiazide diuretics for cost and clinical fit?
Short answer: Diuril (chlorothiazide) competes primarily within the thiazide and thiazide-like diuretic market, where pricing compression is common and therapeutic switching is routine.
Competitive substitutability within thiazide class
- Patients and prescribers generally switch between thiazide agents based on:
- Formulary coverage
- Cost
- Dose tolerance and electrolyte management
- Availability
Where Diuril retains a practical niche
- Where chlorothiazide is preferred or historically used in a facility formulary.
- In settings where a specific dosing form or brand/generic logistics are already established.
What is the Diuril market size, demand drivers, and payer pressure?
Short answer: Demand is steady and low-to-mid single-digit growth (or flat) typical of mature generics. Growth is constrained by:
- Class-level generics competition
- Payer preference for lowest net cost
- Substitution across thiazide agents
Key demand drivers
- Hypertension and edema prevalence.
- Long-term chronic prescribing and maintenance therapy.
- Institutional formularies and medication management systems.
Key dampeners
- Ongoing price erosion from multiple generics.
- Replacement by other diuretics or combination regimens when formularies change.
- Safety monitoring burden and preference for regimens perceived as easier to manage.
What is the 5-year revenue projection for Diuril in the U.S.?
Short answer: With the molecule fully generic and supply competition entrenched, Diuril-branded revenue is projected to remain limited and largely tied to contract/generic mix rather than to brand expansion.
Projection logic for an off-patent legacy brand
A defensible projection in this setting uses:
- Market growth of diuretics (class-level)
- Share shift toward lowest-cost alternatives
- Loss of brand share over time to generics and combination products
- Manufacturing and supply stability impacts
U.S. projection framework (directional)
- Revenue for the Diuril brand: likely flat to slowly declining in nominal terms due to:
- substitution to lower-cost generics
- payer tightening on net cost
- margin compression
- Unit volumes: may stay stable or trend slightly down if prescribers use alternative thiazides more frequently in formularies.
Bottom line: Without evidence of a new differentiated product lifecycle, Diuril’s financial upside is constrained to micro-level share and contract effects, not patent-led growth.
How many generics compete with Diuril chlorothiazide, and how does that affect pricing?
Short answer: Generic competition is broad for chlorothiazide; pricing behavior is driven by multiple ANDA products and periodic supply cycles.
Pricing and margin impact mechanics
- Competitive bidding among wholesalers and pharmacy benefit channels pushes net prices toward the cost floor.
- Margin outcomes depend on:
- contract tender success
- manufacturing yields and scale
- inventory management and backorder risk
What Paragraph IV challenges and ANDA litigation affect chlorothiazide (Diuril)?
Short answer: Paragraph IV litigation is not a major ongoing driver for chlorothiazide because the active ingredient is already generic.
Where litigation still matters
- Rare scenarios: a formulation-specific or method patent tied to a particular dosage form that was filed later than the core compound.
- In such cases, litigation can delay a specific product launch, but it does not change the overall class genericization state.
What formulation patents and method-of-use claims are most relevant for chlorothiazide?
Short answer: The most relevant patent surfaces for an established diuretic are:
- formulation patents (specific release profiles, excipients, fixed combinations)
- manufacturing/process patents (equipment or control processes)
- specific dosing regimens, if any, for a label extension (less common for old molecules)
Why method-of-use patents are typically not a major barrier
For long-generic molecules:
- method-of-use patents rarely block generics unless they cover a still-proprietary claim tied to a current branded product and are asserted effectively in litigation.
Which companies are the main players in chlorothiazide supply?
Short answer: The U.S. supply is typically fragmented across multiple generic manufacturers and distributors.
How to interpret “main players”
For legacy generics, the practical “player list” changes by:
- NDC-level availability
- contract tender wins
- production capacity constraints
- quality issues and recalls
Key risks to the Diuril market outlook
- Continued price erosion: Net cost pressure remains the main risk to revenue.
- Supply disruptions: Shortages or quality holds can create short-term price spikes but generally do not restore sustained brand economics.
- Formulary shifts: Favoring alternative thiazides or combinations can further reduce brand/nostalgia usage.
Key Takeaways
- Diuril (chlorothiazide) is fully genericized; exclusivity and patent timing do not drive market access in the U.S.
- Clinical trial “updates” for Diuril are limited and typically do not reflect new late-stage efficacy innovation; the dominant activity is BE and lifecycle/quality work.
- Market outlook is dominated by generic competition, pricing compression, and formulary substitution within thiazide diuretics.
- A 5-year projection for Diuril-branded revenue trends flat to slowly declining in nominal terms absent a differentiated product event.
FAQs
1) Is Diuril still prescribed in the U.S., and for what conditions?
It is used for hypertension and edema indications consistent with thiazide diuretic labeling and clinical practice patterns for legacy diuretic therapy.
2) Are there any new FDA approvals for chlorothiazide tablets in 2024–2026?
Any approvals in this window are likely ANDA-related lifecycle changes or quality-driven labeling/CMC updates rather than a new molecular entrant.
3) What should procurement teams track for chlorothiazide (Diuril) supply risk?
NDC-level availability, manufacturing holds, inventory lead times, and contract tender outcomes with generic suppliers.
4) Do electrolyte safety issues affect market share for chlorothiazide?
Yes. Monitoring requirements and tolerability influence switching behavior within the thiazide class, especially among patients with comorbidity risk.
5) Can a generic chlorothiazide product be considered fully interchangeable with Diuril?
Typically yes at the active-ingredient level for most clinical use cases, with practical differences driven by dosing, excipients, and formulary coverage.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drugs@FDA: FDA Approved Drug Products. U.S. Food and Drug Administration.
- ClinicalTrials.gov. Chlorothiazide and Diuril search results. U.S. National Library of Medicine.
